diff --git a/pages/STOP2030___Web___Posts.md b/pages/STOP2030___Web___Posts.md
index 5b94ac82..c9eba7d7 100644
--- a/pages/STOP2030___Web___Posts.md
+++ b/pages/STOP2030___Web___Posts.md
@@ -5,10 +5,10 @@
 	- #+BEGIN_VERSE
 	  At STOP2030 we want to provide a pharmacological tool that helps at delivering WHO's goals for soil-transmitted helminthiasis (STH). That is why we're happy to announce that the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness), our most ambitious clinical trial, has been approved for publication in clinicaltrials.gov and the Pan African Clinical Trial Registry.
 	  
-	  This clinical trial is a Cohort Event Study aimed at evaluating the safety and effectiveness of our fixed-dose coformulation (FDC) of albendazol and ivermectin within  large populations, matched against the standard dose albendazole currently in use against STH. We expect to recruit around 20 thousand school-aged children between 5 and 14 years old in Kenya and Ghana.
+	  This clinical trial is a Cohort Event Study aimed at evaluating the safety and effectiveness of our fixed-dose coformulation (FDC) of albendazol and ivermectin within  large populations, matched against the standard dose albendazole currently in use against STH. We expect to recruit around 20 thousand school-aged children between 5 and 17 years old in Kenya and Ghana.
 	  
 	  The general objectives of the REALISE study are to validate the benefits of the FDC through this pragmatic trial in a context of mass drug administration (MDA) programme to evaluate the safety as a primary endpoint and effectiveness profile as a secondary endpoint, in a large population of school-aged children.
 	  
-	  The clinical trial will have two arms, randomized by school. One will be administered a single dose of the fixed-dose coformulation tablet (), while the other, acting as an active control group, will receive a single dose of 
+	  The clinical trial will have two arms, randomized by school. One will be administered a single dose of the fixed-dose coformulation tablet (), while the other, acting as an active control group, will receive a single dose of al
 	  
 	  #+END_VERSE
\ No newline at end of file